MA53275A - Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine - Google Patents

Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine

Info

Publication number
MA53275A
MA53275A MA053275A MA53275A MA53275A MA 53275 A MA53275 A MA 53275A MA 053275 A MA053275 A MA 053275A MA 53275 A MA53275 A MA 53275A MA 53275 A MA53275 A MA 53275A
Authority
MA
Morocco
Prior art keywords
carboxamides
ubiquitin
protease inhibitors
specific protease
specific
Prior art date
Application number
MA053275A
Other languages
English (en)
Inventor
Justin Caravella
Jennifer R Downing
David J Guerin
Stephanos Ioannidis
Hongbin Li
Pui Yee Ng
Tatiana Shelekhin
Zhongguo Wang
Mary-Margaret Zablocki
Original Assignee
Valo Early Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/046061 external-priority patent/WO2019032863A1/fr
Application filed by Valo Early Discovery Inc filed Critical Valo Early Discovery Inc
Publication of MA53275A publication Critical patent/MA53275A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA053275A 2018-08-09 2019-08-08 Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine MA53275A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862716744P 2018-08-09 2018-08-09
PCT/US2018/046061 WO2019032863A1 (fr) 2017-08-11 2018-08-09 Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
US201962788204P 2019-01-04 2019-01-04
US201962805118P 2019-02-13 2019-02-13

Publications (1)

Publication Number Publication Date
MA53275A true MA53275A (fr) 2021-09-15

Family

ID=69457770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053275A MA53275A (fr) 2018-08-09 2019-08-08 Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine

Country Status (12)

Country Link
US (1) US12162888B2 (fr)
EP (1) EP3833661A1 (fr)
JP (1) JP2021534123A (fr)
KR (1) KR20210068010A (fr)
CN (1) CN112867712B (fr)
AU (1) AU2019319907B2 (fr)
BR (1) BR112021002408A2 (fr)
CA (1) CA3108676A1 (fr)
IL (1) IL280486B2 (fr)
MA (1) MA53275A (fr)
MX (1) MX2021001376A (fr)
WO (1) WO2020033707A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801499B1 (fr) 2018-06-07 2024-02-28 Disarm Therapeutics, Inc. Inhibiteurs de sarm1
US12252490B2 (en) 2018-08-09 2025-03-18 Valo Health, Inc. Inhibiting deubiquitinase USP25 and USP28
CA3123215C (fr) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs
CN111909181B (zh) 2019-05-09 2023-02-07 杭州普济远成生物医药科技有限公司 一类泛素化特异性蛋白酶抑制剂及其制备方法与应用
CN111943879A (zh) * 2020-08-03 2020-11-17 南通大学 一种（3s，4r）3-氨基-4（甲氧基甲基）吡咯烷-1-甲酸叔丁酯及其合成方法
CN112898314A (zh) * 2020-11-06 2021-06-04 刘丽萍 去泛素化酶抑制剂的制备与应用
WO2023122298A1 (fr) * 2021-12-22 2023-06-29 Stablix, Inc. Composés de stabilisation de protéines contenant des ligands ciblant usp28 et/ou usp25
US20250289829A1 (en) * 2022-04-28 2025-09-18 Chaser Therapeutics, Inc. Deubiquitinase inhibitor and use thereof
AU2023261809A1 (en) * 2022-04-29 2024-12-05 Asieris Pharmaceuticals (Shanghai) Co., Ltd. Pyrimidine compound, method for preparing same, and pharmaceutical use thereof
CN115246842B (zh) * 2022-06-15 2024-05-24 深圳湾实验室 一类靶向去泛素化酶usp25和usp28的小分子抑制剂
WO2024114793A1 (fr) * 2022-12-01 2024-06-06 杭州普济远成生物医药科技有限公司 Forme saline et forme cristalline d'un inhibiteur de protéase spécifique de l'ubiquitination, leur procédé de préparation et leur utilisation
CN117916246A (zh) * 2022-12-01 2024-04-19 杭州普济远成生物医药科技有限公司 泛素化特异性蛋白酶抑制剂盐型、晶型及其制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078934A2 (fr) 1999-06-22 2000-12-28 School Of Pharmacy, University Of London Diagnostic et traitement de la maladie d'alzheimer
EP1680431A1 (fr) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Compositions de benzothiazole et de thiazole'5,5-b!pyridine et leur utilisation comme inhibiteurs de l'ubiquitine ligase
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
AR075402A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
AU2010218152B2 (en) 2009-02-27 2015-04-09 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of Dengue virus infections
AU2011305315A1 (en) 2010-09-24 2013-03-28 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
DE102012006884A1 (de) * 2012-04-04 2013-10-10 Merck Patent Gmbh Cyclische Amide als MetAP-2 Inhibitoren
CA2896731A1 (fr) 2012-12-28 2014-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibiteurs du complexe usp1/uaf1 desubiquitinase et leurs utilisations
JP2016506929A (ja) 2013-01-23 2016-03-07 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ヒト銅輸送タンパク質ａｔｏｘ１およびｃｃｓを阻害するための方法および組成物
AU2015271099A1 (en) * 2014-06-02 2017-01-12 Pharmakea, Inc. Deubiquitinase inhibitors
MX377305B (es) * 2015-09-14 2025-03-07 Pfizer DERIVADOS DE IMIDAZO[4,5-c]QUINOLINA E IMIDAZO[4,5-c][1,5]NAFTIRIDINA NOVEDOSOS COMO INHIBIDORES DE LRRK2.
BR112018010216B1 (pt) * 2015-11-20 2024-02-15 Forma Therapeutics, Inc Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos
WO2017139779A1 (fr) 2016-02-12 2017-08-17 Forma Therapeutics, Inc. Thiénopyrazine carboxamides en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
US10913753B2 (en) 2016-02-12 2021-02-09 Valo Early Discovery, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
EP3665169A1 (fr) 2017-08-11 2020-06-17 Forma Therapeutics, Inc. Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
US12252490B2 (en) 2018-08-09 2025-03-18 Valo Health, Inc. Inhibiting deubiquitinase USP25 and USP28

Also Published As

Publication number Publication date
KR20210068010A (ko) 2021-06-08
AU2019319907B2 (en) 2024-09-05
BR112021002408A2 (pt) 2021-05-04
WO2020033707A1 (fr) 2020-02-13
JP2021534123A (ja) 2021-12-09
US20210323975A1 (en) 2021-10-21
EP3833661A1 (fr) 2021-06-16
CN112867712A (zh) 2021-05-28
CA3108676A1 (fr) 2020-02-13
AU2019319907A1 (en) 2021-02-18
CN112867712B (zh) 2024-07-16
MX2021001376A (es) 2021-06-23
US12162888B2 (en) 2024-12-10
IL280486A (en) 2021-03-25
IL280486B1 (en) 2024-09-01
IL280486B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MA53275A (fr) Carboxamides en tant qu'inhibiteurs de protéase spécifiques de l'ubiquitine
EP3902802A4 (fr) Compositions pour inhiber la protéase 1 spécifique de l'ubiquitine
MA53816A (fr) Pyrrolines fusionnées qui agissent en tant qu'inhibiteurs de la protéase 30 (usp30) spécifique de l'ubiquitine
IL282103A (en) Furinones as ubiquitin-specific protease 1 inhibitors
MA49841A (fr) Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA42032A (fr) Acides 3-aryl-4-amido-bicyclo [4,5,0]hydroxamiques en tant qu'inhibiteurs de hdac
EP3692028A4 (fr) Inhibition de la peptidase 30 spécifique de l'ubiquitine
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA41291A (fr) Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
MA44725A (fr) Formulations d'un inhibiteur de lsd1
DK3529241T3 (da) Pireridinderivater som inhibitorer af ubiquitin-specifik protease 7
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
MA48800A (fr) Cycles 5-5 fusionnés utilisés en tant qu'inhibiteurs de c5a
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3512839A4 (fr) Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
MA53643A (fr) Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6
MA51202A (fr) Nouveaux dérivés de pipéridinyle utilisés en tant qu'inhibiteurs de la protéase 7 spécifique à l'ubiquitine
EP4023275A4 (fr) Liquide destiné à être atomisé
EP3331887A4 (fr) Benzodiazépines en tant qu'inhibiteurs de bromodomaines
DK4053272T3 (da) Ny serinprotease-variant
FR3034734B1 (fr) Lame d'essuyage pour balai d'essuie-glace
FR3024150B1 (fr) Formulation pour lame de balai d'essuie-glace